The company’s presentation, scheduled for October 4–8, spotlights the MASCOT trial, which tracks 401 participants to evaluate amlenetug’s impact on multiple system atrophy (MSA). This rare neurodegenerative condition lacks disease-modifying therapies, and the upcoming data will detail baseline participant characteristics ahead of final results expected in 2027. Beyond the primary trial, Lundbeck is introducing research into cerebrospinal fluid biomarkers and validated diagnostic scales, aimed at refining early detection and clinical monitoring for MSA patients.

Simultaneously, the firm is addressing the limitations of current Parkinson's disease management. New Phase Ib findings for Lu AF28996, an oral dopamine receptor agonist, offer a potential path for patients struggling with motor fluctuations and dyskinesia—complications that often arise from long-term levodopa therapy. These clinical data are bolstered by preclinical macaque studies, further characterizing the drug's potential to manage motor symptoms without the involuntary movements associated with traditional interventions.